Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Homo sapiens | APEX nuclease (multifunctional DNA repair enzyme) 1 | Starlite/ChEMBL | No references |
Homo sapiens | synuclein, alpha (non A4 component of amyloid precursor) | Starlite/ChEMBL | No references |
Homo sapiens | bromodomain adjacent to zinc finger domain, 2B | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0046 | 0.3679 | 0.3972 |
Loa Loa (eye worm) | hypothetical protein | 0.0085 | 0.9262 | 1 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0072 | 0.736 | 1 |
Brugia malayi | PHD-finger family protein | 0.003 | 0.1356 | 0.1086 |
Loa Loa (eye worm) | hypothetical protein | 0.0049 | 0.4087 | 0.4413 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.0303 | 0.0379 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0072 | 0.736 | 1 |
Echinococcus multilocularis | fetal alzheimer antigen, falz | 0.0027 | 0.0947 | 0.1287 |
Treponema pallidum | exodeoxyribonuclease (exoA) | 0.0023 | 0.0303 | 0.5 |
Echinococcus granulosus | bromodomain adjacent to zinc finger domain | 0.0043 | 0.3258 | 0.4427 |
Wolbachia endosymbiont of Brugia malayi | exonuclease III | 0.0023 | 0.0303 | 0.5 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.1407 | 1 |
Loa Loa (eye worm) | bromodomain containing protein | 0.0021 | 0.0106 | 0.0114 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.1407 | 1 |
Echinococcus granulosus | DNA apurinic or apyrimidinic site lyase | 0.0023 | 0.0303 | 0.0411 |
Entamoeba histolytica | exodeoxyribonuclease III, putative | 0.0023 | 0.0303 | 0.5 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.1407 | 1 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.1407 | 1 |
Echinococcus multilocularis | bromodomain adjacent to zinc finger domain | 0.0043 | 0.3258 | 0.4427 |
Giardia lamblia | Endonuclease/Exonuclease/phosphatase | 0.0023 | 0.0303 | 0.5 |
Echinococcus multilocularis | zinc finger protein | 0.0024 | 0.0435 | 0.0592 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.1407 | 1 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.0303 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0052 | 0.4417 | 0.4769 |
Brugia malayi | hypothetical protein | 0.003 | 0.1407 | 0.1139 |
Schistosoma mansoni | zinc finger protein | 0.0024 | 0.0435 | 0.0546 |
Schistosoma mansoni | hypothetical protein | 0.0025 | 0.0618 | 0.0774 |
Loa Loa (eye worm) | exodeoxyribonuclease III family protein | 0.0023 | 0.0303 | 0.0327 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.1407 | 0.1519 |
Mycobacterium ulcerans | exodeoxyribonuclease III protein XthA | 0.0023 | 0.0303 | 0.5 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.1407 | 1 |
Schistosoma mansoni | acetyl-CoA C-acetyltransferase | 0.0027 | 0.0947 | 0.1188 |
Brugia malayi | Bromodomain containing protein | 0.0046 | 0.3667 | 0.3469 |
Trichomonas vaginalis | ap endonuclease, putative | 0.0023 | 0.0303 | 0.5 |
Schistosoma mansoni | ap endonuclease | 0.0023 | 0.0303 | 0.0379 |
Echinococcus granulosus | fetal alzheimer antigen falz | 0.0027 | 0.0947 | 0.1287 |
Echinococcus multilocularis | DNA (apurinic or apyrimidinic site) lyase | 0.0023 | 0.0303 | 0.0411 |
Echinococcus granulosus | zinc finger protein | 0.0024 | 0.0435 | 0.0592 |
Schistosoma mansoni | bromodomain containing protein | 0.0076 | 0.7978 | 1 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.1407 | 1 |
Loa Loa (eye worm) | PHD-finger family protein | 0.0025 | 0.0618 | 0.0667 |
Mycobacterium tuberculosis | Probable exodeoxyribonuclease III protein XthA (exonuclease III) (EXO III) (AP endonuclease VI) | 0.0023 | 0.0303 | 0.5 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.1407 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.0047 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 0.1 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 1.2589 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of BAZ2B. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504391] | ChEMBL. | No reference |
Potency (functional) | 3.1623 uM | PubChem BioAssay. qHTS of alpha-syn Inhibitors. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 22.3872 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.